SCHEMBL7007545

SCHEMBL7007545

CCC(C)OC(=O)C(Br)C(=O)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.44
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4391353 0.84 FAAH (0.46) FAAHMAPT
SCHEMBL1706068 0.82 MAPT (0.41) FAAHMAPT
SCHEMBL6867730 0.80 MAPT (0.41) FAAHMAPT
SCHEMBL7716571 0.77 FAAH (0.42) FAAHMAPT
SCHEMBL4246694 0.77 FAAH (0.42) FAAHMAPT
SCHEMBL1445320 0.77 MAPT (0.40) FAAHMAPT
SCHEMBL7614587 0.77 MAPT (0.40) FAAHMAPT
SCHEMBL9683369 0.75 FAAH (0.41) FAAHMAPT
SCHEMBL334795 0.75 MAPT (0.44) FAAHMAPT
SCHEMBL11454859 0.75 ALDH1A1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6613775-B1 8-(2,6-dimethylbenzylamino)-2-hydroxymethyl-3-methylimidazo(1, 2-a)pyridine used as antisecretory agents for prophylaxis of gastrointestinal disorders such as ulcers ASTRAZENECA AB (SE) 2003-09-02 US disclosed
EP-1105390-B1 Imidazo[1,2-a]pyridine derivatives for the treatment of gastrointestinal diseases ASTRAZENECA AB (SE) 2003-06-04 EP disclosed
EP-1105390-A2 NEW COMPOUNDS AstraZeneca AB (SE) 2001-06-13 EP disclosed
WO-2000010999-A2 NEW COMPOUNDS ASTRAZENECA AB (SE) 2000-03-02 WO disclosed